Pradaxa and Sputum discolored - a phase IV clinical study of FDA data

Summary:

Sputum discolored is reported as a side effect among people who take Pradaxa (dabigatran etexilate mesylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Symbicort, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Sputum discolored when taking Pradaxa. It is created by eHealthMe based on reports of 86,033 people who have side effects when taking Pradaxa from the FDA, and is updated regularly.

What is Pradaxa?

Pradaxa has active ingredients of dabigatran etexilate mesylate. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 86,906 Pradaxa users. Check the latest studies of Pradaxa.

What is Sputum discolored?

Sputum discolored is found to be associated with 915 drugs and 552 conditions by eHealthMe. Check the latest studies of Sputum discolored.

On Jul, 12, 2026

86,033 people reported to have side effects when taking Pradaxa.
Among them, 25 people (0.03%) have Sputum discolored.

Among these 25 people:

How long have people been on Pradaxa when they have Sputum discolored? *

What is the gender of people who have Sputum discolored when taking Pradaxa? *

female: 32 %
male: 68 %

What is the age of people who have Sputum discolored when taking Pradaxa? *

What are other drugs people take besides Pradaxa? *

What are other side effects people have besides Sputum discolored? *

Dyspnea (difficult or laboured breathing): 15 people, 60.00%
Cough: 14 people, 56.00%
Weight Decreased: 11 people, 44.00%
Fatigue (feeling of tiredness): 7 people, 28.00%
Dizziness: 6 people, 24.00%
Productive Cough: 4 people, 16.00%
Anaemia (lack of blood): 4 people, 16.00%
Memory Loss: 4 people, 16.00%
Fall: 4 people, 16.00%
Hair Loss: 3 people, 12.00%

What are the existing conditions these people have? *

Idiopathic Pulmonary Fibrosis (chronic lung disease): 3 people, 12.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 12.00%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 8.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 4.00%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 4.00%
Joint Pain: 1 person, 4.00%
High Blood Pressure: 1 person, 4.00%
Gout (uric acid crystals building up in the body): 1 person, 4.00%
Enlarged Prostate: 1 person, 4.00%
Dyspnea (difficult or laboured breathing): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Pradaxa and have Sputum discolored?

- Check whether Sputum discolored is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pradaxa:

Pradaxa (86,906 reports)

Browse all side effects of Pradaxa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sputum discolored:

Sputum discolored (915 drugs)

Browse all the conditions that are associated with Sputum discolored:

Sputum discolored (552 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabigatran etexilate mesylate (the active ingredients of Pradaxa) and Pradaxa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.